The HIV-1 pandemic affecting over 37 million people worldwide continues, with nearly one-half of the infected population on highly active antiretroviral therapy (HAART). Major therapeutic challenges remain because of the emergence of drug-resistant HIV-1 strains, limitations because of safety and toxicity with current HIV-1 drugs, and patient compliance for lifelong, daily treatment regimens. Nonnucleoside reverse transcriptase inhibitors (NNRTIs) that target the viral polymerase have been a key component of the current HIV-1 combination drug regimens; however, these issues hamper them. Thus, the development of novel more effective NNRTIs as anti-HIV-1 agents with fewer long-term liabilities, efficacy on new drug-resistant HIV-1 strains, and less frequent dosing is crucial. Using a computational and structure-based design strategy to guide lead optimization, a 5 μM virtual screening hit was transformed to a series of very potent nanomolar to picomolar catechol diethers. One representative, compound I, was shown to have nanomolar activity in HIV-1-infected T cells, potency on clinically relevant HIV-1 drug-resistant strains, lack of cytotoxicity and off-target effects, and excellent in vivo pharmacokinetic behavior. In this report, we show the feasibility of compound I as a late-stage preclinical candidate by establishing synergistic antiviral activity with existing HIV-1 drugs and clinical candidates and efficacy in HIV-1-infected humanized [human peripheral blood lymphocyte (Hu-PBL)] mice by completely suppressing viral loads and preventing human CD4 + T-cell loss. Moreover, a longacting nanoformulation of compound I [compound I nanoparticle (compound I-NP)] in poly(lactide-coglycolide) (PLGA) was developed that shows sustained maintenance of plasma drug concentrations and drug efficacy for almost 3 weeks after a single dose.
HIV-1 | NNRTI | nanoparticle | humanized mice | drug synergy H IV-1/AIDS remains a major challenge as a world health problem, especially in developing countries, with an estimated 37 million people infected with the virus according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) report in 2016 (1) . While there were 2.1 million new infections in 2015, the number of deaths has declined, largely attributable to highly active antiretroviral therapy (HAART). HAART has proven to be effective in suppressing viral replication for the lifetime of an individual (2, 3) , and the number of people on this type regimen has risen to 17 million. The pandemic will likely continue for many years to come in light of the number of individuals currently infected, high rate of new infections, emergence of drugresistant HIV-1 strains, and issues associated with access to therapy, chronic treatment, and patient compliance. For these reasons, the development of novel more effective anti-HIV-1 agents with fewer long-term liabilities and efficacy on new drug-resistant HIV-1 strains is crucial. Moreover, since therapy remains lifelong, improved therapeutic modalities that require less frequent dosing than the current daily regimen would be highly desirable.
The HAART regimen typically includes a combination of three or more antiviral drugs, which target different steps of the HIV-1 replication cycle (4) . Almost 20 y ago, nonnucleoside reverse transcriptase inhibitors (NNRTIs) became part of this regimen alongside nucleoside reverse transcriptase inhibitors (NRTIs). NNRTIs significantly inhibit the catalytic function of HIV reverse transcriptase (RT) by binding in an allosteric binding pocket 10 Å away from the RT polymerase active site and inhibiting the polymerization reaction (5) (6) (7) . Currently, two of the five Food and Drug Administration (FDA)-approved NNRTIs, efavirenz and rilpivirine, are key components of the single-tablet regimens (STRs); Atripla and Complera/Odefsey (8) (9) (10) . Although NNRTIs are key components of effective HAART regimens, their effectiveness is hampered by their poor pharmacokinetic properties, dose-limiting toxicities, and requirement of chronic treatment, which contribute to noncompliance and increasing chances of developing resistance mutations. For instance, the most recently approved NNRTI, rilpivirine, is effective on a number of the most common drug-resistant HIV-1 strains; however, the doselimiting cardiotoxicity caused by inhibition of the hERG (the human Ether-à-go-go-Related Gene)-ion channel (11, 12) restricts its use to patients with viral loads of <100,000 copies. The lower dose of rilpivirine necessary to avoid cardiac-related side effects resulted in higher rate of virologic failure relative to efavirenz in several recent clinical trials (13) .
Over the past several years, our research has focused on developing improved NNRTIs. Our strategy combines state of the Significance Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are essential components of highly active antiretroviral therapy; however, concerns about poor pharmacological properties, dose restriction because of toxicity, and drug resistance have limited treatment options. Our computational and structure-guided design studies for lead optimization have transformed a 5 μM virtual screening hit into a class of NNRTIs with remarkable potency, safety, drug resistance profile, and pharmacological properties. We report a representative, compound I, with marked synergy with existing HIV-1 drugs and antiviral efficacy in HIV-1-infected humanized mice. A single dose of long-acting nanoformulation of compound I retains sustained levels and efficacy for ∼3 weeks, confirming potential as a late-stage preclinical candidate. Additionally, these properties of compound I suggest that it may be a promising candidate to evaluate for preexposure prophylaxis.
art technology for in silico virtual screening/structure-based drug design, synthetic organic chemistry, mechanistic enzymology and protein crystallography, and pharmacological assays (10) (11) (12) . A key component of this computationally guided approach involves the use of free energy perturbation (FEP) calculations to speed lead optimization. FEP-guided lead optimization allowed a 5 μM in silico hit to be transformed into a subnanomolar lead compound. Fig. 1 shows representative steps along the way for improving the diphenylmethane substructure, A, through functionalization to B, further elaboration to a diphenyl ether scaffold C, and additional substituent changes to the difluoro-substituted diphenyl ether, D, which showed potent anti-HIV-1 activity against WT HIV-1-infected T cells. Additional modifications were required to remove the potentially problematic cyanovinyl group and to increase the effectiveness of new compounds on the most common drug-resistant HIV-1 strains as illustrated by the naphthyl catechol phenyl ether compound I. This effort was also enhanced by measurements of aqueous solubility and use of the program QikProp, which informs the selection of compounds with desirable absorption, distribution, metabolism, elimination, toxicity, and drug-like properties (14) (15) (16) (17) .
This effort led to the discovery of a series of catechol diethers that have remarkable potency, efficacy on clinically relevant drugresistant strains of HIV-1, and optimal pharmacological properties, including excellent pharmacokinetics and lack of cytotoxicity and off-target effects (18) (19) (20) . One of the most promising compounds is compound I (Fig. 1) .
In this study, we describe several important milestones achieved for designating a late-stage preclinical candidate, including (i) cellular studies showing potent synergy of the candidate compound with a number of the FDA-approved drugs and clinical candidates for HIV-1, (ii) the development of a long-acting nanoformulation of the compound that produces sustained serum levels for almost 3 wk after a single dose, and (iii) demonstration of the efficacy for the free compound and long-acting nanoparticle (NP) formulation in a humanized mouse model of HIV-1 infection.
Results
Selection of a Late-Stage Preclinical Candidate. Our multifaceted research focused on designing improved NNRTIs led to the discovery of a number of potent catechol diether compounds having excellent antiviral activity in human T cells infected with both WT and drug-resistant strains of HIV-1. Synergy studies. Another consideration for a late-stage preclinical candidate would be an assessment of that compound's behavior in combination with other FDA-approved HIV-1 drugs. A minimum requirement would be that the compound should not be antagonistic with other anti-HIV-1 drugs. Recent cellular studies of doravirine (MK-1439), an NNRTI by Merck in phase III clinical trials for treating HIV-1, showed that the compound was not antagonistic when evaluated for antiviral activity in combination with a number of established AIDS drugs, but no synergy was observed (21) . Ideally, the late-stage preclinical candidate compound should have synergistic anti-HIV-1 effects when evaluated with the current FDA-approved drugs, such as the NRTIs Emtricitabine (FTC) and Tenofovir disoproxil fumarate (TDF) and integrase strand transfer inhibitors (INSTIs), such as elvitegravir (EVG) (22, 23) . In our catechol diether series of compounds, compound I (Fig. 1 ) from this class possessed potent antiviral activity on WT and drug-resistant HIV-1 strains at low nanomolar concentrations, better solubility profiles, and low ClogP [logarithm of a compound's partition coefficient between n-octanol and water log(c octanol /c water )] values compared with rilpivirine (24, 25) and efavirenz (18, 19, 26) . The potential of compound I to exhibit synergistic antiviral effects was determined in HIV-1-infected MT-2 cells with a number of current FDA-approved drugs that are currently used as combination therapy, including FTC, TDF, and EVG. We also evaluated two NRTI clinical candidates 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA or MK-8591) and 4′-ethynyl-2,3-didehydrothymidine (Ed4T or festinavir) that are currently under evaluation in phase I and phase II trials, respectively (27) (28) (29) .
The anti-HIV-1 activity of compound I was evaluated in twodrug combination studies with TDF, FTC, Ed4T, and EFdA in HIV-1-infected MT-2 cells using the HIV-1 IIIB virus strain as described previously (30) . The EC 50 values observed in our MT-2 cell assay for each single drug were 2.8, 85, 100, 2.6, 920, and 1.9 nM for compound I, TDF, FTC, EVG, Ed4T, and EFdA, respectively. An isobologram analysis was conducted to access the potential for synergy. In this analysis, isobolograms are constructed by determining the fractional changes in EC 50 (FEC 50s ) of two anti-HIV-1 agents when used in combination in the MT-2 cellular assay (30) . The values on the additivity line connecting FEC 50 values of one represent an additive interaction between the two compounds, while points markedly below or above the line represent synergy or antagonism, respectively. The combinations of compound I-TDF, compound I-FTC, compound I-EVG, compound I-Ed4T, and compound I-EFdA are shown in Fig. 2 . Compound I showed marked synergy in each case.
The combination inhibitory data were also analyzed using a MacSynergy II [the work by Prichard and Shipman (31) ], a 3D model for statistical evaluation of combination assay. The resulting surface plots of the data reflect the difference between the experimental dose-response surface and the predicted additive surface. On a 3D model, a simple additive effect will result in a horizontal plane at 0% inhibition, whereas a synergistic or antagonistic effect will render a peak or depression above or below the horizontal plane. Fig. 3 shows representative examples of the combination study of compound I with TDF, FTC, EVG, Ed4T, and EFdA. The surface plots generated for each combination showed that the percentage of inhibition was above the horizontal plane, which is indicative of a synergistic effect. The overall performance of the assays was validated by the use of positive control for antagonism [2′,3′-didehydro-3′-deoxythymidine (d4T) in combination with ribavirin] (32). The results are summarized in Table  1 . Hence, the data from isobologram and MacSynergy II analyses establish that synergistic interactions were observed within the concentration ranges examined for antiviral efficacy between compound I, each of the FDA-approved HIV-1 drugs, and clinical candidates used in this study. Since a new agent would likely be used as a combination therapy with existing HIV-1 drugs, the demonstration of synergistic activity for compound I meets a key criterion for a late-stage preclinical candidate. Pharmacological properties. Additional prioritization involved an assessment of in vivo pharmacokinetic behavior as well as the potential for cytotoxicity and off-target effects. In prior studies, the in vitro pharmacological profiling of compound I exhibited no adverse reaction to major targets, such as the hERG channel (20) , the blockade of which is responsible for major cardiac arrhythmias (11) , and showed no inhibition of CYP3A4, which is the major cytochrome P450 enzyme responsible for the metabolism of the majority of currently approved drugs (20) . Moreover, pharmacokinetic studies in BALB/c mice established that compound I displayed a better pharmacokinetic profile compared with efavirenz in a similar study at comparable doses (20 mg/kg) (20, 33) . A single 20-mg/kg dose of compound I produced sufficient levels in serum up to 48 h (Fig. 4A ), which were approximately threefold higher than those previously reported for efavirenz at the same dose (33) . The longer serum residence time and higher serum concentration than required for the therapeutic range make compound I amenable to a daily dose regimen. Furthermore, a higher area under curve (AUC 0-last ) value and a much lower clearance (CL) rate (Table 2 ) compared with efavirenz suggested that compound I can achieve a higher volume of distribution and is subjected to slower metabolism, which is beneficial to maintain optimal control of viral load (20) . In evaluating compounds in vivo to assess pharmacokinetic behavior and efficacy using mouse models to approximate what may be expected in humans, dosages chosen are typically ∼10-fold higher because of the much faster rate of murine metabolism (34) . To offset concerns with higher metabolic rates in murine models, a dosage of 100 mg/kg has been frequently selected for the evaluation of efficacy of antiretroviral agents in humanized mouse models (35) (36) (37) . In our study, a 100-mg/kg dose of compound I administered i.p. into BALB/c mice produced a 10-d serum residence time and showed no morbidity or mortality in BALB/c mice over that period (Fig. 4B , Inset, black circles). A preliminary assessment in a cell-based HIV-1 assay was conducted to establish that sufficient levels of compound I were present in the serum to show antiviral activity. An aliquot of the serum from the pharmacokinetic study was taken at the peak serum concentration (C max ) and at the maximum drug concentration time point (4 h) and evaluated in a TZM-bl-based single-round infectivity cellular assay to prevent HIV-1 infection. The clinical HIV strain JR-CSF of HIV-1 was chosen, as it is commonly used to infect humanized mice. As illustrated in Fig. 4C , in a series of dilutions, the ability to prevent HIV-1 infection is maintained with an IC 50 value of ∼3.2 ± 0.4 nM. Hence, compound I represented a good candidate for sustained administration in a humanized mouse model to evaluate efficacy.
A Long-Acting Nanoformulation of the Late-Stage Preclinical Candidate.
As HAART remains lifelong for those individuals infected with HIV-1, decreasing dosing frequency would be another important criterion for a new HIV-1 therapy. Therefore, concurrent to our studies evaluating a free drug formulation, compound I was further developed into a long-acting nanoformulation. The biodegradable polymer, poly(lactide-coglycolide) (PLGA), was used to produce a long-acting formulation of compound I entrapped in NPs, which can slowly release the compound. Particulate drug delivery systems of PLGA have been approved by the FDA (38), leading to commercial products that reduce the frequency of dosage, alter biodistribution, and improve pharmacokinetics. Development of a long-acting nanoformulation. Compound I was synthesized as described in Materials and Methods and used in the preparation of compound I-loaded PLGA-based NPs (compound I-NPs) using emulsion-solvent evaporation techniques (39) . Compound I-NPs encapsulated in PLGA exhibited an average diameter of 370 ± 9.2 nm, a polydispersity index (PDI) of <0.2, and an average negative zeta potential of −28 ± 0.1 mV (Table 3) . Representative SEM images illustrated that compound I-NP exhibited spherical shapes (Fig. 4D) , and the size estimates from SEM were consistent with the size of compound I-NP reported by dynamic light scattering (DLS). For our first batch, an initial drug loading (DL) of 10 wt % was used, which resulted in DL of 10.5 ± 0.9 wt % and encapsulation efficiency (EE) of 104 ± 26.2% (Table 3) . A second batch of compound I-NPs was made with an initial DL of 15 wt %, resulting in DL of 15.3 ± 1.2 wt % and EE of 95 ± 9.1%. Pharmacokinetics of compound I-NP in BALB/c mice. A detailed pharmacokinetic study of compound I-NP was carried out to determine the dosing and sustainability of compound I-NP in BALB/c mice. A single dose of compound I-NP (20 or 125 mg/kg) from the first batch of NPs was injected into mice i.p., and blood samples were collected for a total of 35 d. Fig. 4A , Inset, solid red circles compares the serum concentrations of compound I administered as NP with free drug (Fig. 4A , Inset, solid black circles) at a dose of 20 mg/kg. A substantially longer period of compound I presence for up to 35 d was observed in mice that received the nanoformulation, whereas compound I levels were below the limit of detection in serum by day 2 in mice receiving free compound I. The serum drug concentration of 0.2 μg/mL for compound I-NP-treated mice on day 35 was substantially greater (>100-fold) than the EC 50 for the WT HIV-1 in the MT-2 assay (18). The C max of compound I in NPs (3.9 ± 0.2 μg/mL, 4 h postinjection) was threefold lower than the C max of 11.8 μg/mL for free injected compound I (Fig. 4A,  Inset) . The pharmacokinetic parameters are summarized in Table 2 . The AUC 0-last (472.9 ± 20.9 μg/mL per hour) was approximately two times higher and the CL (0.7 mL/min per kilogram) was approximately two times lower than free compound I (AUC 0-last : 209.2 ± 23.1 μg/mL per hour and CL: 1.5 mL/min per kilogram). The serum concentration-time curve for compound I-NP at the 125-mg/kg dose showed C max of 4.25 ± 0.6 μg/mL 4 h postinjection (Fig. 4B, Inset) . Detectable levels of compound I were observed for up to 35 d with a concentration of 0.33 ± 0.12 μg/mL on day 35, which was much greater than the EC 50 (19) and similar to that obtained with the 20-mg/kg dose of free compound I. Fig. 4B also compares the serum levels of mice injected with free compound I at 100 mg/kg. Additional analyses of pharmacokinetic data for free and nanoformulated compound I showed that the AUC 0-last (709.5 ± 43.9 μg/mL per hour) and total body CL (2.9 mL/min per kilogram) in mice receiving compound I-NP were comparable with the AUC 0-last (706 ± 185 μg/mL per hour) and CL (2.3 mL/min per kilogram) for mice injected with free compound I (Table 2) . Hence, the data suggest that nanoformulation of compound I provides a slow and sustained release of compound I in BALB/c mice. Moreover, serum concentrations of compound I were maintained well above the required therapeutic levels for a prolonged period of time, even after a single dose of nanoformulated compound I. These studies show the potential of the compound I-NP as a promising, long-acting nanoformulation that should be further evaluated. Anti-HIV activity of compound I-NP in infected TZM-bl cells. Fig. 4E depicts the inhibition of HIV-1 infection for compound I-NP. The concentrations of compound I-NP in serum samples collected after dosing with the nanoformulation on days 14, 19, 22, 30, and 35 were sufficient to achieve 100% inhibition of HIV-1 infection [0.1 multiplicity of infection (MOI)] in TZM-bl cells at a serum volume of 10 μL (Fig. 4E, solid blue circles) . A complete inhibition of HIV-1 infection was also observed with free compound at 4 h postinfection (Fig. 4E, black circle) . These data suggest that a single administration of compound I-NP may be able to provide similar protection for up to 35 d, which was comparable with that observed after 4 h in mice given free compound I. Collectively, the synergy studies, pharmacokinetic and pharmacological evaluations, and development of a long-acting nanoformulation with compound I fulfill important criteria for a late-stage preclinical candidate and provide a firm basis for the efficacy studies in humanized mice described below. /SzJ mice that are reconstituted with human peripheral blood lymphocyte (NSG-Hu-PBL) were chosen. These NSG-Hu-PBL mice are reconstituted with activated T cells and can, therefore, be readily infected with HIV-1 JR-CSF strain to produce an infection causing a rapid loss of CD4
+ T cells within a few days of infection (41, 42) . On the basis of the data described above, we selected compound I (free drug) at the 100-mg/kg dose for in vivo studies in HIV-1 JR-CSF -infected NSG-Hu-PBL mice to assess efficacy of the late-stage preclinical candidate. Using this humanized mouse model, we compared in vivo efficacy of free compound I injected daily with a single dose of compound I-NP given i.p. to HIV-1 JR-CSF -infected NSG-Hu-PBL mice. The antiretroviral activity of free and nanoformulated compound I was evaluated by looking at the preservation of CD4 + T cells and determination of plasma viral loads (PVLs) in NSG-Hu-PBL mice.
Pharmacokinetics of compound I and compound I-NP in JR-CSF-infected
NSG-Hu-PBL mice. Experiments with free compound I and compound I-NP were performed in four groups of NSG-Hu-PBL mice infected with HIV-1 JR-CSF (30,000 pfu) as shown in the scheme in Fig. 5A . Starting 1 d before HIV-1 infection (day −1), one group was treated with free compound I at 100 mg/kg per day for up to 19 d, after which the drug was withdrawn to assess the viral rebound and thus, productive infection (withdrawal group). The second group was treated with free compound I at 100 mg/kg per day for 32 d (continuous group). Mice in the third group received a single dose of 190 mg/kg compound I-NP from the second batch of NPs, where EE was higher. Several recent reports have evaluated HAART in nanoformulation at dosing ranging from 200 to 250 mg/kg (43, 44) . Therefore, for the efficacy studies, we chose a dose of 190 mg/kg for compound I-NP. A fourth group of mice received no treatment and was marked as the control group.
The serum concentrations of free and nanoformulated compound I in mice were determined on days 8, 16, 25, and 32 and were compared with the control group (Fig. 5B) . Fig. 5B shows that comparable levels of compound I were observed in serum of all treated groups until day 16. On day 25, there was a greater than fourfold increase in serum levels of compound I in mice from the continuous group in contrast to the withdrawal group and compound I-NP group (Fig. 5B , solid red circles and solid blue circles, respectively). High serum levels of compound I were maintained until day 32 in the mice from continuous group. Accordingly, the serum concentrations of compound I became undetectable on day 32 in the withdrawal group, but these mice maintained serum levels comparable (14.6 μg/mL) with those of the continuous group on day 16. The compound I-NP group maintained 14.5 μg/mL of compound I in serum until day 16, which was similar to the continuous group. There was a threefold reduction in compound I serum concentrations on day 25 in compound I-NP-treated mice. These data suggest that one single injection of compound I in nanoformulation is able to maintain comparable serum levels of compound I compared with the group that received free compound daily for 32 d. (Fig. 6 ). The loss of human CD4 + T cells caused by the HIV-1 infection in reconstituted immunodeficient mice provides an indicator of viral infection (41, 45) . Thus, levels of human CD4
+ and CD8 + cells as a percentage of total human CD3 + T cells and CD4 + /CD8 + T-cell ratio were determined from FACS analyses of blood samples (Fig. 6 A and B) , which compares Mice receiving free compound I were further divided into two groups. Mice in group I (green circles) received 100 mg/kg of free compound I daily until day 32, whereas mice in group II (red circles) stopped receiving compound I on day 19. For both the groups, the serum drug levels were determined on days 8, 16, 25, and 32. After i.p. administration of 190 mg/kg of compound I-NP (blue circles) on day −1, serum levels of compound I were determined on days 8, 16, 25, and 32. Data points represent ±SD. the no treatment, 100 mg/kg per day of compound I, and 190-mg/kg single-dose compound I-NPs over a period of 32 d. On the day of infection, CD4 + T-cells levels were comparable in all four groups of mice (Fig. 6 A and B, open black circles) . Low levels of CD4 + T cells (∼2%) were observed in the control group by 2 wk postinfection. CD4
+ T-cells levels were preserved in all treatment groups at 2 wk post-HIV-1 JR-CSF inoculation (69.3 ± 2, 71.6 ± 0.8, and 70.6 ± 0.8% of total cells in continuous, withdrawal, and compound I-NP groups, respectively). While CD4 + T cells in mice from the continuous group were maintained to 60.6 ± 4.7 and 50 ± 4.3% at weeks 3 and 4, respectively, mice in the withdrawal group had reduced CD4 + T cells (32.1 ± 2.5%) by week 4. In mice receiving compound I-NP, the CD4 + T cells were maintained at 47.7 ± 11.8 and 25.1 ± 8.3% through weeks 3 and 4, respectively.
In all treatment groups, we found that compound I reduced HIV-1 RNA by 3 log 10 (1,000-fold; from a mean of 10 7 HIV-1 RNA copies in untreated mice to 10 4 copies in treated mice) by day 8 and by 4 log 10 (10,000-fold from a mean of 10 7 HIV-1 RNA copies in untreated mice to 10 3 copies in treated mice) by day 16 post-HIV-1 JR-CSF inoculation. The continuous daily administration of free compound I at 100 mg/kg per day after HIV-1 JR-CSF inoculation reduced viremia to undetectable levels (<150 copies) in all mice within 19 d of compound I treatment, and the viral loads remained undetectable after 4 wk (Fig. 6C, solid green circles) . Accordingly, in the withdrawal group, when treatment was stopped at day 19 (Fig. 6C , solid red circles and withdrawal denoted by star), viremia rebounded at week 3 to 10 4 copies (similar to that on day 8 posttreatment) and increased to 10 5 copies on withdrawal of free compound I by days 25 and 32. This is reflected in the drop of CD4 + T cells in Fig. 6B . PVL of mice treated with a single dose of compound I-NP (Fig. 6C , solid blue circles) was below detection limit until day 19 and increased to 10 4 and 10 5 copies only by days 25 and 32, respectively. In each of the latter two cases, the viremia rebound was accompanied by a drop in the plasma concentration of compound I. These data indicate that continual exposure of free or a single dose of long-acting compound I effectively controls virus replication in NSG-Hu-PBL mice. Discussion HAART as a combination therapy is the current standard of care to prevent HIV-1 infection or resistance development. The HIV/ AIDS pandemic will continue for many years, underscoring the need for developing novel more effective therapies. Considerations for improved anti-HIV-1 agents include fewer issues with long-term toxicity, ability to counteract emergence of new drugresistant variants, and a long-acting formulation that requires less frequent dosing. Moreover, synergistic activity with existing HIV-1 drugs would offer added value as components of combination therapy. Our computational and structure-guided strategy focused on designing NNRTIs has yielded a potent series of catechol diether compounds with favorable pharmacokinetic and toxicological profiles (18) (19) (20) . In this study, compound I (Fig. 1) was selected for additional consideration as a late-stage preclinical candidate. Important criteria to meet for advancement were (i) synergy with existing FDA-approved drugs and clinical candidates, (ii) suitability as a long-acting formulation, and (iii) efficacy in a disease-relevant animal model for HIV-1 infection. This study represents the culmination of an effort to design enhanced NNRTIs that provide advantages over the current FDA-approved NNRTIs. A major benefit for any NNRTI, as part of a combination HAART regimen, would be the ability to exhibit antiviral synergy with existing NRTIs or other classes, such as INSTIs. Therefore, the first criterion examined for compound I was whether it could potentiate the antiviral potency of NRTIs in HIV-1-infected human T cells. The NRTIs chosen were FTC or TDF, as they are components of STRs, Atripla and Complera. The INSTI EVG was selected to examine another class of AIDS drugs, as it is currently being evaluated in a long-acting formulation with rilpivirine in the Long-Acting Antiretroviral Treatment Enabling (LATTE) Trial (46) . In addition, Ed4T and EFdA were examined. Ed4T (festinavir), a more potent, less toxic derivative of D4T (Zerit), was chosen, as it has shown promising results in phases I and II clinical trials (27, 47) . EFdA (MK-8591), a very potent new NRTI being developed by Merck, was selected, as it has also shown promising results in late-stage preclinical and early phase I clinical trials (28, 29, 47) . As illustrated in the isobologram and MacSynergy II plots in Figs. 2 and 3 , compound I showed strong synergy with all of the compounds tested representing current STR regimens (FTC and TDF) and another HIV-1 drug class, INSTIs (EVG). These characteristics of compound I confer advantages over the NNRTI doravirine (MK-1439) currently being evaluated in phase III trials, which only showed nonantagonistic behavior with other HIV-1 agents (21) .
A second criterion taken into account was the suitability of compound I for development of a long-acting formulation. Biodegradable PLGA NPs were used to encapsulate compound I as a strategy to reduce the daily dosage by prolonged and sustained release. Characterization of compound I-NPs showed that it was encapsulated in PLGA NPs with the appropriate particle size (370 ± 9.2 nm) and zeta potential (−28 ± 0.1). The negative zeta potential suggests that compound I-NP could have prolonged circulation time in vivo by escaping uptake in cells and tissues (48, 49) . A prolonged circulation time for compound I-NP was confirmed by preliminary pharmacokinetic studies. When a single 20-or 125-mg/kg dose of compound I-NP was administered i.p. to BALB/c mice, detectable levels of compound I in mouse serum were observed for 35 d (Fig. 4 A and B) , confirming a substantially longer residence time. Additionally, the serum levels of ∼0.5 μg/mL of compound I-NP on day 35 were significantly higher than the concentrations required to inhibit HIV-1 replication in cells in our MT-2 (20) and TZM-bl assays (Fig. 4C) . The encapsulation of compound I prevented the burst or rapid release of the drug from NP (50) as seen by 3-and 10-fold lower C max levels at 20-and 100-mg/kg doses, respectively, compared with free injected compound I. Additional analysis of pharmacokinetic data at the 20-mg/kg dose indicated that the AUC 0-last of compound I-NP was twofold higher and that the total body CL was twofold lower compared with free injected compound I. The observed AUC 0-last value (472.9 ± 20.9) of compound I-NP at 20 mg/kg was also twofold higher compared with the AUC 0-last value (230.6 ± 80.6 μg h/mL) of efavirenz observed in a similar pharmacokinetic study in BALB/c mice (33) . The larger AUC 0-last value and the lower CL value could suggest that a higher volume of distribution can be achieved by compound I-NP because of prolonged release of compound I and also, that encapsulation of compound I leads to a slower metabolism. In contrast, the AUC 0-last and CL of compound I-NP at higher dose were comparable with those of free injected compound I. Hence, comparison of pharmacokinetic profiles of free and nanoformulated compound I suggests that a single dose of compound I-NP displays a longer residence time of over a month when administered in an equivalent dose as free compound I in BALB/c mice. Additionally, the serum levels observed in pharmacokinetic study were well above the therapeutic concentrations, which could provide good protection against acute loss of CD4 + T cells and could also decrease viral loads to eradicate HIV-1 from the anatomically privileged sites, where free drug concentrations can be subtherapeutic (51, 52 ). An initial assessment of the antiviral efficacy ex vivo for the compound I-NPs was provided by examining the ability of the serum aliquots from each time point to inhibit HIV-1 infection in TZM-bl cells infected with HIV-1 JR-CSF strain (Fig. 4E) . The prolonged residence time, serum levels above the therapeutic concentration for compound I-NP, and confirmation of antiviral activity in HIV-1-infected cells retained even at the 35-d collection suggest that single dosing of compound I-NP should suffice for maintaining a good virus control and that it has an excellent potential for use as a long-acting anti-HIV-1 NNRTI.
The third criterion, perhaps the most crucial for compound I as a late-stage preclinical candidate, was an assessment of efficacy in HIV-1-infected NSG-Hu-PBL mice. The design of the treatment groups to evaluate efficacy is illustrated in Fig. 5A . Earlier pharmacokinetic studies with compound I given as an i.p. dose of 100 mg/kg to BALB/c mice indicated that sufficient levels of compound remained after 24 h, prompting consideration as a once daily dose (20, 37) . The efficacy for the treatment group against HIV-1 infection was assessed by examining two key parameters: loss of CD4 + T cells as an indicator of HIV-1 infection and the PVL, which reflects the efficiency of viral replication. The i.p. administration of compound I-NP and free compound I in HIV-1-infected Hu-PBL-NSG mice clearly showed the striking antiviral potency of this catechol diether NNRTI (Fig. 6) . A daily i.p. administration of compound I at 100 mg/kg prevented the acute loss of CD4 + T cells in HIV-1-infected NSG-Hu-PBL mice as determined from FACS analysis (Fig. 6A) , preserved this population of cells by almost 90% after 2 wk, and protected HIV-1 in these mice by reducing PVLs to undetectable levels ( Fig. 6 B and C, solid green and red circles). These mice showed plasma viral levels with 3-to 4-log 10 decreases within 8-16 d of initiation of treatment. A similar preservation of CD4 + T cells and decrease in plasma viral levels were observed with a single dose of compound I-NPs in the 2-wk period (Fig. 6 B and C, solid blue circles). As anticipated, for the withdrawal group, viremia rebounded in 10 d after treatment cessation (Fig. 6C, solid red  circles) . However, the viral rebound was slower, and the PVLs were similar to ones seen within 8 d posttreatment initiation. The treatment with a single dose of compound I-NP halted acute CD4 + T-cell loss and decreased PVL until day 25 posttreatment in HIV-1-infected NSG-Hu-PBL mice, while in the continuous group, the viral load remained undetectable for the entire 32 d of the study. Hence, these studies have shown that treatment of HIV-1-infected NSG-Hu-PBL mice with a single dose of compound I-NP a day before infection suppresses plasma HIV-1 viral load and prevents the acute loss of CD4 + T cells for almost 3 wk, which is comparable with mice receiving free compound I daily.
Taken together, the data presented in this study show the potent antiviral activity of compound I in free and nanoformulated forms in HIV-1-infected Hu-PBL-NSG mice. The experiments reported here established the feasibility of using PLGA compound I-NPs as a long-acting drug delivery system, which was able to provide a sustained and prolonged release of compound I in mice. Additionally, given the potential to be combined with other anti-HIV-1 drugs with synergistic effect, lack of toxicity and effects on hERG ion channel and CYP3A4 (20) , and effectiveness against clinically relevant drug-resistant HIV-1 strains (i.e., Y181C, K103N, K101P/E, E138K, M184V) (53), compound I exhibits exceptional properties as an NNRTI for the treatment of HIV-1 infection that could provide durable clinical antiviral efficacy. Considering that extended duration anti-HIV-1 agents in combination with other drugs are the main focus of emerging HIV-1 therapies, compound I is a promising late-stage preclinical candidate that warrants full development. One of the emerging HIV-1 therapies, preexposure prophylaxis (PrEP), holds the promise of eliminating new infections along with the associated risks of HIV infection. Hence, the qualities of compound I, synergistic effects with other HIV-1 drugs, and ease of formulation to a long-acting drug with potent antiviral activity make it a good candidate to additional study as a PrEP formulation.
Materials and Methods
Chemicals and Synthesis of Compound I. Poly(d,l lactic-coglycolic-acid), 50:50 with inherent viscosity 0.95-1.20 dL/g, was purchased from DURECT Corporation. Compound I was synthesized as detailed previously (19) .
Preparation of Humanized Mice. NOD.Cg-Prkdc SCID Il2rg tm1Wjl /SzJ (NSG) mice were purchased from the Jackson Laboratory. All experiments were performed according to protocols approved by the Institutional Review Board and the Institutional Animal Care and Use Committee of Yale University. NSG-Hu-PBL mice were prepared by engrafting peripheral blood mononuclear cells (PBMCs) as described (42, 54) . Briefly, 5-7 × 10 6 PBMCs purified by Ficoll density gradient centrifugation of healthy donor blood (obtained from the New York Blood Bank) were injected i.p. in a 200-μL volume into 7-to 10-wk-old NSG mice. Cell engraftment was checked 14 d postinjection as described previously; 50-100 μL of blood was collected by retroorbital bleeding. PBMCs were isolated by Ficoll density gradient centrifugation; stained with Fluor-conjugated anti-human CD45, CD3, CD4, and CD8 antibodies; and analyzed by flow cytometry to confirm engraftment.
Fabrication of Compound I-NPs. Briefly, 100 mg of PLGA polymer was dissolved in dichloromethane at a concentration of 50 mg/mL. Compound I was dissolved separately in 200 μL of DMSO and added to the polymer solution. The aqueous phase consisted of 4 mL of 5% polyvinyl alcohol. An emulsion of the solutions was created through dropwise addition of the polymer/drug solution to the aqueous solution under vortex followed by three cycles (10 s each) of sonication using a probe sonicator (amplitude 38%). NPs were collected by centrifugation at 16,100×g. Trehalose was added as a cryoprotectant at 100% (wt/wt) before lyophilization.
Characterization of Compound I-NPs. NP size, PDI, and zeta (ζ) potential were measured by DLS by resuspending 0.05 mg NPs in 1 mL deionized water using a Zetasizer Nano ZS90 (Malvern Instruments). SEM images were obtained on an XL-30 scanning electron microscope (FEI; Hilsboro). To measure surface charge (zeta potential), NPs were diluted in deionized water at a concentration of 0.5 mg/mL; 750 μL of solution was loaded into a disposable capillary cell (Malvern Instruments), and the charge was measured using a Malvern Nano-ZS. The abbreviations used in SEM image are: Acc. V, accelerating voltage; Det, detector; Exp, exposure number; Magn, magnification; Spot, technical term that describes the width of the SEM beam, usually defined in reference to the center point of the beam (reference point and value may change based on specific SEM unit); and WD, working distance. Reverse-phase HPLC was used to measure DL (%), which is defined as the measured mass of compound I per mass of PLGA NP, and EE (%), which is defined as the ratio of the compounds loaded to the total drugs used for fabricating the NPs: DLð%Þ = mass of compound I in NPs total mass of NPs × 100 EEð%Þ = mass of drug in NPs mass of polymer used in formulation × 100.
Briefly, DL was determined by dissolving a known mass of lyophilized compound I-NP in DMSO. The samples were filtered by using an Acrodisc 25-mm syringe filter with a 0.45-μm HT Tuffryn membrane (Pall Life Sciences) followed by additional dilution in acetonitrile. The samples were analyzed using the HPLC system as previously described in detail (20) .
Pharmacokinetic Studies. To determine dose-dependent serum drug concentrations, in vivo pharmacokinetics of free compound I and compound I-NP was investigated in BALB/c mice (20 mg), which were obtained from the Jackson Laboratory. BALB/c mice were randomly divided into four groups containing three mice each. Two groups of mice were injected i.p. with 20 or100 mg/kg of free compound I suspended in sterile saline solution containing 10% Tween 80. The other groups was injected i.p. with 20 and 125 mg/kg compound I-NP suspended in sterile saline solution. These doses corresponded to human doses of 1.6-10.2 mg/kg based on an interspecies scaling factor of 12.3 (36) . The blood samples were collected at predetermined time points from the ocular venous plexus by retroorbital venipuncture and used for subsequent analysis as detailed previously.
HIV-1 Challenge in Humanized Mice, Pharmacokinetic Studies, and Antiretroviral Activity of Free Compound I and Compound I-NP. HIV-1 infection and maintenance of infected mice were done in the BSL-3 animal facility under standard caging conditions. Twelve NSG mice were divided into four groups of n = 3: control or no treatment, free compound I injected at 100 mg/kg per day for a total of 35 d, free compound I withdrawn on day 19, and compound I-NP (single dose at 190 mg/kg on day 0). One day after the treatment, animals were challenged i.p. with HIV-1 JR-CSF [30,000 Tissue Culture Infectious Dose (TCID 50 )] and were bled retroorbitally to check the levels of CD4 + T cells and the PVLs. Serum levels of compound I were analyzed on days 8, 16, 19, 25, and 32 after retroorbital venipuncture using HPLC as described earlier. On day 19, free compound I was withdrawn from one group (n = 3), and the mice were observed for viral rebound. Additionally, pharmacokinetic studies in these mice were carried out as previously described for BALB/c mice.
Quantification of PVLs and FACS Analyses of T-Cell Subsets. Quantification of PVLs was done using the method described previously (55) . Briefly, plasma viral RNA was extracted using the QIAamp viral RNA mini kit (QIAGEN) following the manufacturer's protocol. SYBR green real-time PCR assay was carried out in a 20-μL PCR mixture volume consisting of 10 μL of 2× Quantitect SYBR green RT-PCR Master Mix (Qiagen) containing HotStarTaq DNA polymerase, 0.5 μL of 500 nM each oligonucleotide primer, 0.2 μL of 100× QuantiTect RT Mix (containing Omniscript and Sensiscript RTs), and 8 μL of RNA extracted from plasma samples or standard HIV-1 RNA (from 5 × 10 5 to 5 copies per 1 mL). Highly conserved sequences on the gag region of HIV-1 were chosen, and specific HIV-1 gag primers were selected (56) . The sequences of HIV-1 gag primers are 5′ TGCTATGTCAGTTCCCCTTGGTTCTCT 3′ and 5′ AGTTGGAGGACATCAAGCAGCCATGCAAAT 3′. Amplification was done in an Applied Biosystems 7500 real-time PCR system, and it involved activation at 45°C for 15 min and 95°C for 15 min followed by 40 amplification cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 30 s. For the detection and quantification of viral RNA, the real-time PCR of each sample was compared with threshold cycle value of standard curve. For FACS analysis, 50-100 μL of blood was collected by retroorbital bleeding on days 8, 16, 19, 25, and 32. PBMCs were isolated by Ficoll density gradient centrifugation; stained with Fluor-conjugated anti-human CD45, CD3, CD4, and CD8 antibodies; and analyzed by flow cytometry to assess CD4 + T-cell levels.
Measurement of the Inhibitory Activity of Compound I-NP in Infected TZM-bl Cells. The in vitro anti-HIV-1 activity of free compound I and compound I-NP was determined using a luciferase reporter gene assay as described previously (20) .
Combination Study. The combination inhibitory effects of compound I and different drugs (TDF, FTC, EVG, Ed4T, and EFdA) were tested in a two-drug combination as described previously (30, 57) . The combination inhibitory data were analyzed using isobologram analysis and MacSynergy II 3D plots (31) . For isobologram analysis, isobolograms were constructed by measuring the FEC 50 values of two anti-HIV-1 agents when used in combination in the MT-2 assay (30) . The values on the additivity line connecting FEC 50 values of one represent an additive interaction between the two compounds, while points markedly above or below the line represent antagonism or synergy, respectively. The combination inhibitory effect of compound I was also analyzed using the MacSynergy II 3D model by Prichard and Shipman (31) . Ribavirin and d4T were used as the positive controls as an antagonism pair (32, 58) . The resulting surface plots of the data reflect the difference between the experimental doseresponse surface and the predicted additive surface. On a 3D model, a simple additive effect will result in a horizontal plane at 0% inhibition, whereas a synergistic or antagonistic effect will render a peak or depression above or below the horizontal plane. 
